-
Pharmaceuticals and drug discovery
Botanix Pharmaceuticals
Research Watch now → Context Therapeutics
Research Watch now → Diurnal Group
Research Watch now → Hexima
Research Watch now → InMed Pharmaceuticals
Research Watch now → IRLAB Therapeutics
Research Watch now → Medlab Clinical
Research Watch now → Mesoblast
Research Watch now → Midatech
Research Watch now → Oasmia
Research Watch now → Sareum Holdings
Research Watch now → Tryp Therapeutics
Research Watch now → -
Novel approach
Actinogen Medical
Research Watch now → Aditxt
Research Watch now → AlzeCure Pharma
Research Watch now → Avalo Therapeutics
Research Watch now → BiondVax
Research Watch now → Cantargia
Research Watch now → Kazia Therapeutics
Research Watch now → Oxford Biomedica
Research Watch now → Renaissance BioScience
Research Watch now → Scandion Oncology
Research Watch now → SIGA Technologies
Research Watch now → Verici Dx
Research Watch now → The Open 100
Watch now → -
AI and technology
Belluscura
Research Watch now → Carmat
Research Watch now → Evogene
Research Watch now → Imagion Biosystems
Research Watch now → IONIQ Sciences
Research Watch now → LungLife AI
Research Watch now → OpGen
Research Watch now → VolitionRx
Research Watch now → Volpara Health
Research Watch now →
Register
To receive updates on the event and the companies attending, please fill in the form below
Botanix Pharmaceuticals
Matt Callahan, executive director
Botanix Pharmaceuticals Limited is an ASX-listed dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of novel treatments for common skin diseases and infections that are underpinned by science and supported by well-controlled, randomised clinical trials.
https://vimeo.com/669506219/aea6af899d
Context Therapeutics
Martin Lehr, CEO
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with hormone-dependent cancer.
https://vimeo.com/669506798/d8b7e279ee
Diurnal
Martin Whitaker, CEO
Diurnal Group is a specialty pharma company developing new formulations of hormone-based products for the treatment of endocrine disorders. Its product Alkindi is marketed for paediatric (AI) in the US and EU. Efmody is approved for the treatment of CAH in the EU and UK.
https://vimeo.com/669507326/aa93ea5d4c
Hexima
Michael Aldridge, CEO
Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis).
https://vimeo.com/669508016/f28197fd3b
InMed Pharmaceuticals
Eric Adams, CEO
InMed is a pharmaceutical company focused on developing and manufacturing cannabinoids. Its main pipeline product is INM-755 for EB, a serious, debilitating orphan indication.
https://vimeo.com/669718299/ce01fedc64
IRLAB Therapeutics AB
Dr Nicholas Waters, CEO
IRLAB is dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS).IRLAB strive to transform the everyday life for patients who lack effective treatment options.
https://vimeo.com/669508495/e6e6710f60
Medlab Clinical
Dr. Sean Hall, CEO
Medlab Clinical is an Australian biotechnology company that is developing therapeutics using its proprietary delivery platform NanoCelle. Its most advanced programme is in cancer pain management with lead drug candidate NanaBis, a medicinal cannabis product for cancer-related bone pain.
https://vimeo.com/669510137/7c80bece61
Mesoblast
Dr. Silviu Itescu, CEO
Mesoblast is developing adult stem-cell therapies based on its proprietary MPC and MSC platforms. Its lead programmes are in pediatric aGvHD, heart failure, ARDS and lower back pain, all of which are in Phase III or later.
https://vimeo.com/669511799/3c5de2a585
Midatech
Stephen Stamp, CEO and CFO
Midatech is a drug-delivery specialist focused on re-engineering therapeutics through its technology platforms (MidaSolve- local drug-delivery, QSphera- sustained-release, MidaCore – targeted delivery) to improve their bioavailability and delivery.
https://vimeo.com/669508621/1e08636fd9
Oasmia
Francois Martelet, CEO
Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health.
https://vimeo.com/669507347/4e23250158
Sareum Holdings
Dr. Tim Mitchell, CEO
Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors.
https://vimeo.com/669507078/c735323e5c
Tryp Therapeutics
Greg McKee, CEO
Tryp Therapeutics is leading psychedelic drug development beyond mental health.
https://vimeo.com/669505375/95a922320f
Outlook for healthcare equity financing in 2022
Perspectives on public, private markets and sector investment themes.
Hosted by London Stock Exchange Group
Chair:
Chris Mayo, Head of Primary Markets, Americas, LSEG
Speakers:
Randy Baron, Portfolio Manager, Pinnacle Associates
Tom Stockman, Head of European Healthcare Investment Banking, RBC
Shahram Seyedin Noor, Founder, Civilization Ventures
https://vimeo.com/669799528/6911142ddd
Actinogen Medical
Dr. Steven Gourlay, CEO
Actinogen Medical is an ASX-listed Australian biotech developing lead asset Xanamem, a brain-penetrant 11beta-HSD1 inhibitor designed to treat cognitive impairment and other symptoms that occurs in chronic neurological diseases.
https://vimeo.com/669797818/a46ddf9cb1
Aditxt
Amro Albanna, CEO
Aditxt is a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring.
https://vimeo.com/669797898/0fe2a1ba7b
AlzeCure Pharma
Martin Jönsson, CEO
AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing small molecule drugs for the treatment of Alzheimer’s disease (symptomatic and disease modifying) and pain (neuropathic and osteoarthritic).
https://vimeo.com/669798102/33d1bc9143
Avalo
Michael Cola, CEO
Avalo is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.
https://vimeo.com/669798153/43cb07beab
BiondVax
Josh Phillipson, Director of Business Development and Investor Relations
Biondvax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.
https://vimeo.com/669798366/b4fb4f1494
Cantargia
Göran Forsberg, CEO
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
https://vimeo.com/669798407/69364f3e51
Kazia
Dr. James Garner, CEO
Kazia Therapeutics’ lead asset is paxalisib, a PI3K inhibitor licensed from Genentech that can cross the BBB. It is entering a pivotal study for GBM and is being investigated for other brain cancers such as breast cancer brain metastases.
https://vimeo.com/669799383/5add9084b3
Oxford Biomedica
John Dawson, CEO
Oxford Biomedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector research and bioprocessing. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
https://vimeo.com/669800362/b7c5161135
Renaissance BioScience
Dr. John Husnik, CEO
Renaissance BioScience is an Environmental Impact company whose bioengineering platform technologies develop innovative, market-ready, functional microorganisms that provide solutions to a broad range of health and environmental problems.
https://vimeo.com/669800518/a5be74fa5e
Scandion Oncology
Bo Rode Hansen, president and CEO
Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
https://vimeo.com/669797499/5595b9f4ff
SIGA Technologies
Dr. Phillip Gomez, CEO
SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxviruses. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox.
https://vimeo.com/669797551/12d8fda789
Verici Dx
Sara Barrington, CEO
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
https://vimeo.com/669797604/b119f7fdd0
The Open 100
The OPEN 100 is a chance for healthcare CEOs to tell the world about a world-changing innovation, trend or product coming our way. Expect passion and revelation in equal amounts as the future comes into view in these ten talks each lasting just ten minutes.
https://vimeo.com/667812443/5cddde985f
The trends: 2022
What will distinguish 2022’s healthcare innovations from previous years? What new trends will emerge? Which will accelerate? How many will start to fade?
Chair:
Neil Shah, Head of Content, Edison Group
Speakers:
Tom Burt, Partner, Sofinnova Partners
Gareth Powell, Head of Healthcare, Polar Capital
Jennifer Friel Goldstein, Managing Partner, Silicon Valley Bank
View the panel live from OpenExchange’s platform via the link below.
https://edison-open-house.videoshowcase.net/day-2
Belluscura
Robert Rauker, CEO
Belluscura is a publicly traded UK company listed on the AIM submarket of the London Stock Exchange (AIM: BELL). Belluscura focuses on developing and commercialising innovative oxygen enrichment technologies that span broad industries and therapies.
https://vimeo.com/669798309/27ba34d43a
Carmat
Stéphane Piat, CEO
Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. It received a CE mark in the EU and Carmat is conducting an early feasibility study in the United States.
https://vimeo.com/669798449/6f09b95fb7
Evogene
Ofer Haviv, president and CEO
Evogene (NASDAQ:EVGN, TASE: EVGN.TA) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
https://vimeo.com/669799200/20cc3e8daf
Imagion Biosystems
Bob Proulx, president and CEO
Imagion Biosystems Limited manufactures and supplies medical equipment. The Company offers a bio-imaging detection technology that uses disease specific targeting nanoparticles and highly sensitive detectors to locate tumors and other diseased cells by their molecular signature.
https://vimeo.com/669799279/08ec696264
IONIQ Sciences
Jared Bauer, CEO
IONIQ Sciences is at the forefront of early cancer detection. IONIQ Sciences is decoding the science of the body’s earliest response to the presence of cancer.
https://vimeo.com/669799329/90ee9eff84
LungLife AI
Paul Pagano, CEO
LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.
https://vimeo.com/669800253/4b9e790021
OpGen
Oliver Schacht, CEO
OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.
https://vimeo.com/669800309/5e7fd2da29
VolitionRx
Cameron Reynolds, President & CEO
VolitionRx Limited manufactures epigenetic cancer detection blood tests. The Company’s tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types.
https://vimeo.com/669797691/c391218faa
Volpara Health
Ralph Highnam, CEO
Volpara Health’s origins go back to our founding CEO Ralph Highnam’s breakthrough research in medical physics and artificial intelligence at the University of Oxford. Volpara has seen tremendous growth by almost every measure.
https://vimeo.com/669797760/a3bed371d1
Current trends and hot topics in biopharma partnering
Hosted by Taylor Wessing
https://vimeo.com/667812406/12964da678